Ozempic Shows Promise for Mood Stability in Bipolar Disorder

Australian researchers analyzed 15,000 people over 15 years and found that semaglutide (Ozempic) lowered the risk of psychiatric hospitalization in bipolar disorder by about 21%, a benefit not seen with related GLP-1 drugs. The findings suggest GLP-1 signaling may protect the brain by reducing inflammation and cellular stress, potentially improving mood stability, though more research is needed to confirm direct effects on bipolar symptoms.